Market capitalization | $37.92m |
Enterprise Value | $-36.99m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.72 |
EV/Sales (TTM) EV/Sales | -61.65 |
P/S ratio (TTM) P/S ratio | 63.20 |
P/B ratio (TTM) P/B ratio | 0.54 |
Revenue (TTM) Revenue | $600.00k |
EBIT (operating result TTM) EBIT | $-70.00m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
5 Analysts have issued a Rallybio Corp forecast:
5 Analysts have issued a Rallybio Corp forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.60 0.60 |
-
|
|
Gross Profit | 0.46 0.46 |
407%
407%
|
|
EBITDA | -70 -70 |
7%
7%
|
EBIT (Operating Income) EBIT | -70 -70 |
7%
7%
|
Net Profit | -67 -67 |
5%
5%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focuses in the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.
Head office | United States |
CEO | Stephen Uden |
Employees | 43 |
Founded | 2018 |
Website | www.rallybio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.